Principal Scientist, Protein Drug Discovery & Development

**Exciting opportunity in upscaling the future Y-mAbs Therapeutics**

**Y-mAbs Therapeutics** is a fast-paced, growing company in the process of expanding its organization

to support the continuous growth and the exciting clinical pipeline with activities in both early and

late-stage clinical development.

Y-mAbs Therapeutics is establishing an in-house focus area of protein engineering within the CMC governance area. The focus area of protein engineering will support the growing pipeline of future product candidates. They are therefore looking for a Principal Scientist with both a strong scientific knowledge within protein engineering and with an entrepreneurial mindset to lead and grow this focus area. The candidate will join the CMC Development team.

**With direct report** to Senior Director CMC Development.

**Your main tasks are:**

* Designing and modeling the first antibody campaigns, based on identified targets, immunizations or available sequence information, and collaborate on an optimal screening strategy throughout the lead selection process, based on structural and biochemical insight
* Collaborating with the Sci Director on the biochemical and biophysical characterization to secure that the initial and lead candidates are designed and expressed with the desired product attributes to secure mode of action, physical, and chemical stability as well as robust manufacturability
* Operate as a link between R&D Science, the Translational Medicine group, and CMC Development
* Add protein chemistry and engineering/modeling expertise to the lead selection process governed by Y-mAbs R&D Scientific Lab under the juristriction of the Chief Scientific Officer
* Drive the protein engineering development and growth of this new focus area to support the diverse Y-mAbs development portfolio including mono- and bispecific antibody formats and novel protein-based constructs
* Identify and oversee the right CROs for protein engineering campaigns
* Directly steer and influence discussions and decisions related to the development of an appropriate drug modality

**You have extensive experience** from the pharmaceutical industry in engineering, modeling, and

characterization of protein and antibody variants as clinical leads together with in depth experience

in structure/function-based techniques and protein design tools. Moreover, you have experience

with therapeutic protein drug discovery and development and with protein expression. Finally, you

have experience with analytical set-up for selection of product candidates and with working with

CROs.

**You have a Master’s degree** in a relevant scientific area. A PhD is preferred, but not a demand.

As a person, you have acan-do attitude and a positive and proactive approach. You have the ability to work independently with multiple tasks and under ambitious timelines. Furthermore, you have great analytical skills, eye for details and good planning and problem handling abilities, while you find it natural to cooperate with various stakeholders internally, as well as externally.

**Y-mAbs Therapeutics** offers an exciting opportunity in a successful biotech company, in which you will have a high degree of influence on your own job. The position will allow you to create a sustainable footprint while developing professionally and upscaling the future Y-mAbs.

Travelling: Approx. 10-20 days per year.

Domicile: Y-mAbs office in Hørsholm, Denmark.

Unique Human Capital is handling the recruitment. For more details about the job or the company, please contact CEO Jørn Duhn, Unique Human Capital on M: +45 21 75 19 25 or Senior Research Consultant Elisabeth Haun, Unique Human Capital on M: +45 28 90 33 88. All applications must be in English and are treated confidentially.

You can apply directly via this link:

<https://uhc.dk/en/available-jobs/principal-scientist-protein-drug-discovery-development/>

*Y-mAbs Therapeutics is a late-stage clinical biopharmaceutical company focused on the development*

*and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.*

*The company has a broad and advanced product pipeline, including 1 FDA approved and 1 pivotal-*

*stage product candidate – naxitamab and omburtamab – which target tumors that express GD2 and*

*B7-H3, respectively.*

*Y-mAbs’ mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. With the right partnerships and collaboration, they envision expanding their capabilities to treat adults – changing the course of cancer care and its outcomes. Currently, there are 140+ permanent employees in Y-mAbs.*

*Read more at* [*www.ymabs.com*](http://www.ymabs.com)*.*